SCHEMBL6285598

SCHEMBL6285598

CC(C)c1cnc(NC(=O)N2CCN(c3ccc(F)cc3)CC2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 1/20 0.58
GLA P06280 1/20 0.52
CCNE1 P24864 4/20 0.51
CDK2 P24941 4/20 0.51
CDK5 Q00535 4/20 0.51
ALDH1A1 P00352 2/20 0.51
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA9 Q16790 2/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 7/20 0.50
RECQL P46063 1/20 0.50
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PKM P14618 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GFER P55789 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285286 0.88 MAPT (0.59) PANK3CCNE1CDK2CDK5ALDH1A1
SCHEMBL6287931 0.87 KMT2A (0.54) CCNE1CDK2CDK5ALDH1A1CA12
SCHEMBL7083762 0.83 CDK2 (0.49) CCNE1CDK2CDK5MAPTNPC1
SCHEMBL6287957 0.81 CYP2C19 (0.53) CCNE1CDK2CDK5ALDH1A1POLB
SCHEMBL27570633 0.81 CDK2 (0.61) PANK3CCNE1CDK2CDK5ALDH1A1
SCHEMBL6282734 0.81 CDK2 (0.61) CCNE1CDK2CDK5ALDH1A1KDM4E
SCHEMBL6286715 0.81 CCNE1 (0.54) PANK3CCNE1CDK2CDK5ALDH1A1
SCHEMBL6288095 0.80 CDK2 (0.46) PANK3CCNE1CDK2CDK5ALDH1A1
SCHEMBL6284830 0.80 CDK2 (0.59) CCNE1CDK2CDK5ALDH1A1MEN1
SCHEMBL7837765 0.79 CCNE1 (0.45) CCNE1CDK2CDK5ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1325390-A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2001-12-05 CN claimed
US-20190330167-A1 ACTIVATORS OF HIV LATENCY THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2019-10-31 US disclosed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed
CN-1325390-A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2001-12-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330167-A1 ACTIVATORS OF HIV LATENCY NFATC1, EP300, CD69 PANK3 3061/4885GLA 264/4885CCNE1 785/4885
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 PANK3 756/4885GLA 4046/4885CCNE1 83/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 PANK3 756/4885GLA 4046/4885CCNE1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.